Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 5/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632299 | 0.89 | L3MBTL1 (0.48) | SRD5A2MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL5459285 | 0.84 | PDE4A (0.57) | NR4A1SMN1; SMN2ALDH1A1L3MBTL1PDE4A | |
| SCHEMBL3232949 | 0.79 | SRD5A2 (0.90) | SRD5A2MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL5457259 | 0.78 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL402300 | 0.77 | SRD5A2 (0.87) | SRD5A2MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL5457930 | 0.76 | PDE4A (0.69) | SRD5A2SMN1; SMN2HTTL3MBTL1PDE4A | |
| SCHEMBL5630998 | 0.75 | PDE4A (0.50) | SMN1; SMN2ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL3415530 | 0.74 | SRD5A2 (0.81) | SRD5A2MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL10876870 | 0.74 | NPC1 (0.47) | SRD5A2MAOBSMN1; SMN2ALDH1A1PLA2G4B | |
| SCHEMBL31556120 | 0.74 | ALDH1A1 (0.78) | SRD5A2MAOBNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| WO-2004058726-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | SRD5A2 1144/4885MAOB 193/4885NR4A1 1052/4885 |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | PDE3A, PDE4A, PDE3B | SRD5A2 1207/4885MAOB 740/4885NR4A1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.